[go: up one dir, main page]

AU2016250905A8 - Generation of muscle-lineage cells from stem cells - Google Patents

Generation of muscle-lineage cells from stem cells Download PDF

Info

Publication number
AU2016250905A8
AU2016250905A8 AU2016250905A AU2016250905A AU2016250905A8 AU 2016250905 A8 AU2016250905 A8 AU 2016250905A8 AU 2016250905 A AU2016250905 A AU 2016250905A AU 2016250905 A AU2016250905 A AU 2016250905A AU 2016250905 A8 AU2016250905 A8 AU 2016250905A8
Authority
AU
Australia
Prior art keywords
cells
muscle
generation
lineage
stem cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2016250905A
Other versions
AU2016250905A1 (en
AU2016250905B2 (en
Inventor
Leslie Caron
Uli Schmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sonic Master Ltd
Original Assignee
Sonic Master Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sonic Master Ltd filed Critical Sonic Master Ltd
Publication of AU2016250905A1 publication Critical patent/AU2016250905A1/en
Publication of AU2016250905A8 publication Critical patent/AU2016250905A8/en
Assigned to Genea Biocells USA (Holdings), Inc. reassignment Genea Biocells USA (Holdings), Inc. Request for Assignment Assignors: GENEA IP HOLDINGS PTY LTD
Assigned to SONIC MASTER LIMITED reassignment SONIC MASTER LIMITED Request for Assignment Assignors: Genea Biocells USA (Holdings), Inc.
Application granted granted Critical
Publication of AU2016250905B2 publication Critical patent/AU2016250905B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • C12N5/0659—Satellite cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)

Abstract

Methods and compositions for producing cells expressing CD56/Pax3, CD56Pax7, and/or Pax3/Pax7 are provided herein. In some instances, the method involves contacting a pluripotent stem cell in an
AU2016250905A 2015-04-22 2016-04-22 Generation of muscle-lineage cells from stem cells Ceased AU2016250905B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562151352P 2015-04-22 2015-04-22
US62/151,352 2015-04-22
PCT/AU2016/000144 WO2016168890A1 (en) 2015-04-22 2016-04-22 Generation of muscle-lineage cells from stem cells

Publications (3)

Publication Number Publication Date
AU2016250905A1 AU2016250905A1 (en) 2017-11-09
AU2016250905A8 true AU2016250905A8 (en) 2018-03-15
AU2016250905B2 AU2016250905B2 (en) 2022-02-10

Family

ID=60254709

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016250905A Ceased AU2016250905B2 (en) 2015-04-22 2016-04-22 Generation of muscle-lineage cells from stem cells

Country Status (7)

Country Link
US (1) US20180346879A1 (en)
EP (1) EP3286301B1 (en)
JP (1) JP7055638B2 (en)
CN (1) CN107709545A (en)
AU (1) AU2016250905B2 (en)
CA (1) CA2983332A1 (en)
WO (1) WO2016168890A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2731437T3 (en) 2014-11-21 2019-11-15 Regeneron Pharma Methods and compositions for directed genetic modification through the use of guide RNA pairs
WO2017100498A1 (en) * 2015-12-11 2017-06-15 The Johns Hopkins University Isolation of fusion-competent myoblasts and therapeutic applications thereof related to muscular dystrophy
US20190338251A1 (en) * 2016-04-27 2019-11-07 Takeda Pharmaceutical Company Limited Skeletal Muscle Precursor Cells and Production Method for Skeletal Muscle Cells
MX2018014172A (en) 2016-05-20 2019-08-22 Regeneron Pharma Methods for breaking immunological tolerance using multiple guide rnas.
WO2018076060A1 (en) * 2016-10-26 2018-05-03 Genea Ip Holdings Pty Ltd Improved generation of muscle lineage cells and therapeutic uses thereof
EP3565887B1 (en) * 2017-01-06 2025-07-16 The Regents of The University of California Methods for generating skeletal muscle progenitor cells
CN107937338B (en) * 2017-11-30 2021-08-03 中山大学 Mesenchymal stem cell of mesoderm lineage derived from pluripotent stem cells and preparation method thereof
CN110859854A (en) * 2018-08-08 2020-03-06 上海市东方医院 Medicinal composition for treating neurogenic muscle atrophy, preparation method and application thereof
JP7033095B2 (en) * 2019-03-04 2022-03-09 日清食品ホールディングス株式会社 Three-dimensional muscle tissue and its manufacturing method
JP2023502269A (en) * 2019-11-20 2023-01-23 ヴィータ セラピューティクス インク． Genetically modified preparation of low immunogenic muscle progenitor cells
JP7540893B2 (en) * 2020-02-27 2024-08-27 テルモ株式会社 Composition for increasing the ratio of CD56 positive cells
CN111826451A (en) * 2020-09-11 2020-10-27 中国肉类食品综合研究中心 Primer group for real-time fluorescent quantitative PCR detection of porcine muscle regulatory factor and application thereof
WO2022093665A1 (en) * 2020-10-26 2022-05-05 University Of Massachusetts Methods and compositions for treatment of muscle disease with ipsc-induced human skeletal muscle stem cells
WO2022140300A1 (en) * 2020-12-22 2022-06-30 Ixcells Biotechnolgies Usa, Inc. Methods and compositions for differentiating skeletal muscle
CN117795059A (en) * 2021-08-09 2024-03-29 阿利夫农场公司 Muscle cells differentiated from pluripotent cells, methods of production and uses thereof
KR20240152443A (en) * 2023-04-12 2024-10-22 이엔셀 주식회사 A method for screening a therapeutic agent of disease associated with muscular weakness

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143842A (en) 1988-11-01 1992-09-01 The University Of Colorado Foundation, Inc. Media for normal human muscle satellite cells
JP5149791B2 (en) * 2006-04-28 2013-02-20 第一三共株式会社 Method for inducing differentiation of cardiomyocytes from pluripotent stem cells
CN103228782B (en) * 2010-06-13 2016-03-30 中国科学院生物物理研究所 Methods and compositions for preparing cardiomyocytes from stem cells and uses thereof
EP2825637A4 (en) * 2012-03-14 2015-12-23 Childrens Medical Center IMAGING-BASED IMAGING HIGH-PERFORMANCE CHEMICAL SCREENING FOR FISH-ZEBRA BLASTOMER CELL CULTURE
CN107460164B (en) * 2012-07-23 2021-02-05 中国科学院生物物理研究所 Method for differentiating pluripotent stem cells into ventricular myocytes by in vitro induction
AU2014268197A1 (en) * 2014-02-11 2015-08-27 Monash University Muscle cell production
CN104293730B (en) * 2014-09-23 2017-07-28 云南中科灵长类生物医学重点实验室 Multipotential stem cell vitro directed differentiation is the method for cardiac muscle cell
WO2016108288A1 (en) * 2014-12-29 2016-07-07 国立大学法人京都大学 Method for producing skeletal muscle progenitor cells

Also Published As

Publication number Publication date
CA2983332A1 (en) 2016-10-27
WO2016168890A8 (en) 2017-11-30
WO2016168890A1 (en) 2016-10-27
US20180346879A1 (en) 2018-12-06
AU2016250905A1 (en) 2017-11-09
CN107709545A (en) 2018-02-16
JP2018518943A (en) 2018-07-19
EP3286301A1 (en) 2018-02-28
EP3286301A4 (en) 2019-02-20
JP7055638B2 (en) 2022-04-18
AU2016250905B2 (en) 2022-02-10
EP3286301B1 (en) 2021-07-28

Similar Documents

Publication Publication Date Title
AU2016250905A8 (en) Generation of muscle-lineage cells from stem cells
ZA202310779B (en) Compositions and methods for enhanced gene expression
SG10201810150UA (en) Compositions and methods for enhanced gene expression in cone cells
EP3161127A4 (en) Cultured mammalian limbal stem cells, methods for generating the same, and uses thereof
WO2016012544A3 (en) Enhanced reprogramming to ips cells
TW201612312A (en) Meristematic plant cells and method of isolating them
GB2548740A (en) Methods for generation of podocytes from pluripotent stem cells and cells produced by the same
MX2016014235A (en) ERGOTIONEINE MICROBIAL BIOSINTESIS.
MX2020000621A (en) Methods and compositions for immunomodulation.
BR112017018885A2 (en) cell culture method for mesenchymal stem cells
EP4282869A3 (en) Lithium-ion battery electrolyte and lithium-ion battery
EP3234110A4 (en) METHODS FOR GENERATING STEM CELL-DERIVED ß CELLS AND USES THEREOF
TW201612308A (en) Collector architecture layout design
EP3118307A4 (en) Activator for mesenchymal stem cells, activated mesenchymal stem cells, and method for producing same
EP3279212A4 (en) Method for mass producing proteins in mesenchymal stem cells
EP3263697A4 (en) Culture medium for culturing mesenchymal stem cell, method for culturing mesenchymal stem cell, and mesenchymal stem cell
EP4470544A3 (en) Methods and compositions for reprogramming cells
EP3587559A4 (en) Production method for artificial pluripotent stem cells
EP3202896A4 (en) Method for culturing pluripotent stem cells
HK1254740A1 (en) Methods for differentiating and purifying pancreatic endocrine cells
EP3866816A4 (en) Mesenchymal stem cell derived exosomes and methods
EP3750987A4 (en) Cell population including adhesive stem cells, production method therefor, and pharmaceutical composition
WO2015171852A3 (en) Methods and compositions for non-cytotoxic stem cell transplantation
MX2022000516A (en) Methods relating to pluripotent cells.
EP3733838A4 (en) Cell population including adhesive stem cells, method for producing such cell population, and pharmaceutical composition

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 31 , NO 44 , PAGE(S) 6426 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME GENEA IP HOLDINGS PTY LTD, APPLICATION NO. 2016250905, UNDER INID (31) CORRECT THE PRIORITY TO 62/151,352

PC1 Assignment before grant (sect. 113)

Owner name: GENEA BIOCELLS USA (HOLDINGS), INC.

Free format text: FORMER APPLICANT(S): GENEA IP HOLDINGS PTY LTD

PC1 Assignment before grant (sect. 113)

Owner name: SONIC MASTER LIMITED

Free format text: FORMER APPLICANT(S): GENEA BIOCELLS USA (HOLDINGS), INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired